DVA

Business Context and Reporting Period

Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: DaVita is a leading provider of dialysis services. The reporting period includes the full integration of the DVA Renal Healthcare acquisition (completed October 2005), which significantly expanded the company's scale. The company operates outpatient dialysis centers and provides related services, with a significant portion of revenue derived from government programs (Medicare/Medicaid) and commercial payors.

Key Financial Metrics

Note: Debt and Cash figures represent balances as of June 30, 2006. Operating cash flow is presented for the six-month period.

Material Changes vs. Prior Period

• Revenue Growth: Net operating revenues increased approximately 96% year-over-year for the quarter and 98% for the six-month period. This growth is primarily attributable to the acquisition of DVA Renal Healthcare, which contributed approximately $500 million in revenue for the quarter and $975 million for the six months.
• Operating Expenses: Patient care costs rose to 69.8% of revenues in Q2 2006 (from 67.3% in Q2 2005), driven by higher labor/benefit costs and increased pharmaceutical intensity. General and administrative expenses increased due to integration costs and the implementation of FAS 123(R).
• Debt Expense: Debt expense increased significantly to $68.4 million for the quarter (from $24.9 million in 2005) due to borrowings used to fund the DVA acquisition. The effective interest rate was approximately 6.60% for the quarter.
• Provision for Uncollectible Accounts: The provision increased to 2.6% of revenues in 2006 compared to 1.8% in 2005, a level management expects to remain stable.

Guidance, Outlook, and Risks

Guidance and Outlook

• Operating Income: Management revised 2006 operating income guidance upward to a range of $670 million to $700 million (previously $600 million to $680 million).
• Cash Flow: The company expects to generate approximately $450 million to $500 million in operating cash flow for 2006.
• Capital Expenditures: Expected to spend $125-$135 million on maintenance/IT and $150-$180 million on new center development and acquisitions in 2006.

Material Risks and Contingencies

• Government Investigations: The company is cooperating with multiple subpoenas from U.S. Attorney's Offices (Missouri, New York, Pennsylvania) regarding billing practices, pharmaceutical services, and financial relationships with physicians. Potential outcomes include substantial penalties or exclusion from Medicare/Medicaid.
• Supply Agreement Dispute: On May 29, 2006, DaVita notified Gambro Renal Products of terminating their Alliance and Product Supply Agreement due to alleged material breach (failure to supply equipment). Resolution is ongoing.
• Regulatory Changes: Risks include potential declines in commercial payor rates, changes to Medicare ESRD payment structures (specifically regarding pharmaceuticals like EPO), and Medicaid eligibility changes.
• Accounting Changes: The company adopted FAS 123(R) effective January 1, 2006, resulting in the recognition of stock-based compensation expense ($11.5 million for the six months ended June 30, 2006).

Investor Verification Checklist

• Integration Progress: Verify the successful integration of DVA Renal Healthcare billing and collection systems and the realization of anticipated cost synergies.
• Legal Exposure: Monitor the status of the U.S. Attorney investigations and the potential financial impact of penalties or settlements.
• Supply Chain Stability: Assess the resolution of the dispute with Gambro Renal Products and the impact on equipment availability and costs.
• Reimbursement Rates: Track changes in commercial payor contracts and Medicare pharmaceutical payment policies (EPO coverage).
• Debt Servicing: Confirm the company's ability to service its substantial debt load ($3.9 billion long-term) amidst potential revenue fluctuations.